Avadel Pharmaceuticals PLC (AVDL)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
AVDL
Avadel Pharmaceuticals PLC
$21.64
0.00%
HEALTHCARE · Cap: $2.12B
TAK
Takeda Pharmaceutical Co Ltd ADR
$18.95
+0.32%
HEALTHCARE · Cap: $60.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 1858499% more annual revenue ($4.62T vs $248.52M). AVDL leads profitability with a -0.0% profit margin vs -3.5%. AVDL appears more attractively valued with a PEG of 0.07. TAK earns a higher WallStSmart Score of 53/100 (C-).
AVDL
Hold41
out of 100
Grade: D
TAK
Buy53
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.2%
Fair Value
$70.24
Current Price
$21.64
$48.60 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Growing faster than its price suggests
Reasonable price relative to book value
Generating 73.8B in free cash flow
Large-cap with strong market position
Areas to Watch
0.5% revenue growth
0.0% earnings growth
Operating margin of 0.0%
Weak financial health signals
ROE of 2.4% — below average capital efficiency
Earnings declined 9.8%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AVDL
The strongest argument for AVDL centers on PEG Ratio. PEG of 0.07 suggests the stock is reasonably priced for its growth.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, Free Cash Flow. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bear Case : AVDL
The primary concerns for AVDL are Revenue Growth, EPS Growth, Operating Margin.
Bear Case : TAK
The primary concerns for TAK are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
AVDL carries more volatility with a beta of 1.63 — expect wider price swings.
TAK is growing revenue faster at 10.2% — sustainability is the question.
TAK generates stronger free cash flow (73.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TAK scores higher overall (53/100 vs 41/100) and 10.2% revenue growth. AVDL offers better value entry with a 69.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Avadel Pharmaceuticals PLC
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Avadel Pharmaceuticals plc is a biopharmaceutical company in the United States. The company is headquartered in Dublin, Ireland.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?